Sofia Lugo's mission at Radar Therapeutics is deeply rooted in her family's struggle to access healthcare after moving to the US. This injustice fueled her desire to build a more equitable system, demonstrating how personal adversity can become a powerful motivator for large-scale innovation.
While mRNA vaccines were a triumph, mRNA therapeutics have never been approved. Therapeutics require higher protein production and precise cellular targeting, a far greater technical challenge than the broad immune response stimulated by vaccines. This distinction is a major blind spot for the public.
Many current gene therapies require a complex "ex vivo" process: removing cells, reprogramming them in a lab, and reinfusing them. The true breakthrough is developing "in vivo" treatments administered via a simple infusion that autonomously target the correct cells within the body.
The next leap in medicine isn't just delivering a payload but programming it with conditional logic. Radar Therapeutics engineers mRNA to act like software with "if/and/or" commands. This allows the therapy to sense its cellular environment and activate only in the right context, moving beyond a simple "execute" function.
Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.
While "programmable medicine" excites investors, it creates fear among patients, evoking images of being chipped or controlled. To build public trust, biotech communication must pivot from technological coolness to the core patient needs: safety and efficacy.
In a stable market, experience is an asset. But in a disruptive industry like today's biotech, experienced leaders may rely on outdated playbooks. First-time executives can be more valuable because they approach problems from first principles, unburdened by past successes that are no longer relevant.
The typical path for a new, high-risk biology is to test it in patients with no other options, like in oncology. The COVID-19 pandemic forced a massive deviation from this norm. For the first time, a completely new class of medicine (mRNA) was deployed at scale in healthy individuals, not the sickest.
Instead of being a deterrent, having a genuinely hard scientific problem is a powerful recruiting tool. It attracts curious, convention-challenging people who are motivated by solving what others cannot and are willing to work through ambiguity to achieve a breakthrough.